Indian Journal of Palliative Care
Open access journal 
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size Users online: 152  
     Home | About | Feedback | Login 
  Current Issue Back Issues Editorial Board Authors and Reviewers How to Subscribe Advertise with us Contact Us Analgesic Prescription  
  Navigate Here 
 Search
 
  
 Resource Links
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (267 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this Article
   References

 Article Access Statistics
    Viewed90    
    Printed0    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents 
COMMENTARY
Year : 2020  |  Volume : 26  |  Issue : 4  |  Page : 535-536

Fentanyl, morphine, and opioid-induced constipation in patients with cancer-related pain


Department of Palliative Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India

Date of Submission18-Sep-2019
Date of Acceptance02-Nov-2019
Date of Web Publication19-Nov-2020

Correspondence Address:
Arunangshu Ghoshal
Department of Palliative Medicine, Tata Memorial Hospital, Mumbai - 400 012, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/IJPC.IJPC_171_19

Rights and Permissions



How to cite this article:
Ghoshal A. Fentanyl, morphine, and opioid-induced constipation in patients with cancer-related pain. Indian J Palliat Care 2020;26:535-6

How to cite this URL:
Ghoshal A. Fentanyl, morphine, and opioid-induced constipation in patients with cancer-related pain. Indian J Palliat Care [serial online] 2020 [cited 2020 Dec 3];26:535-6. Available from: https://www.jpalliativecare.com/text.asp?2020/26/4/535/300791




Opioid drugs are known to inhibit gastric emptying and peristalsis in the gastrointestinal (GI) tract, which results in delayed absorption of medications and increased absorption of fluid. At the receptor level, in the GI tract, the mu and delta receptors predominate and are found in the myenteric and submucosal plexus. The opioid receptors stimulate the production of adenylate cyclase and inhibit the calcium channels, which, in turn, results in a decrease in neurotransmitter release. Tolerance to opioids not only develops pain but also the pharmacological effects on the GI tract.[1],[2] The lack of fluid in the intestine leads to hardening of stool and constipation. Most patients with opioid-induced constipation complain of straining and incomplete emptying of the rectum during defecation. Opioids also increase the anal sphincter tone impairing the defecation reflex. Moreover, opioids have been found to decrease emptying of pancreatic juice and bile leading to delayed digestion.[3],[4],[5]

In the article “A comparative study of transdermal fentanyl patch versus sustained release oral morphine in patients on palliative care with regard to bowel function discomfort, ”the authors found that patients converted from oral morphine to transdermal fentanyl reported a significant improvement in constipation. This comparison has been around in published literature for quite some time. Although the results of randomized trials are conflicting,[6],[7],[8],[9],[10] two systematic reviews of patients receiving opioids for cancer and noncancer pain concluded that there is less constipation with transdermal fentanyl than with oral sustained-release morphine.[11],[12] There have been no direct comparisons of the constipating effects of these drugs, and in the absence of anecdotal reports of differential effects on the gut, the explanation for these observations has focused on the route of administration. The nonoral route presumably impacts opioid receptors less than the oral route and, for this reason, may be less constipating. Other proposed mechanisms include the reduction of first-pass metabolism, the difference between a 12-h and 72-h sustained-release delivery system, and/or a combination of all three.[6],[7],[8],[13],[14],[15],[16],[17],[18],[19] Furthermore, in this context, we should also be aware of an alternative hypothesis proposed by Grunkemeier et al. regarding the opioid withdrawal syndrome.[20],[21] According to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition criteria, signs and symptoms of opioid withdrawal include lacrimation or rhinorrhea, piloerection “goose flesh, ”myalgia, diarrhea, nausea/vomiting, pupillary dilation and photophobia, insomnia, autonomic hyperactivity (tachypnea, hyperreflexia, tachycardia, sweating, hypertension, and hyperthermia), and yawning.[22] Davies et al. have suggested that opioid withdrawal syndrome can significantly bias the results in short-term studies (for example, the present one), and so, we should be aware of this entity while choosing between opioids in this matter.

The present study conducted at Palliative Care Center, R.K. Birla Cancer Center, SMS Hospital, Jaipur, compares two opioids, each in a different formulation – oral or transdermal. This is a welcome trial in a difficult area. The focus is which drug (or formulation) gives the fewest problems or is preferred by patients, at the same level of pain relief. Unfortunately, the design of the trial means that we must question the results. Rule one of drug trials that compare different formulations and use subjective outcomes such as patient preference is that the comparison should be done double-blind. This may be awkward, and it will be more expensive, but breaking the convention means that the conclusions may not be correct. Yet here, we are with a study which compared different formulations and used subjective outcomes and was not done double-blind. The problem we are left with is whether any difference between formulations is credible, and whether any credible difference is worthwhile given the marked price difference between the two products.[23] Given the high prevalence of cancer pain and its major impact on quality of life, it is time that we had a better grip on what works in clinical practice and when.

Acknowledgment

To the authors of “A comparative study of transdermal fentanyl patch versus sustained-release oral morphine in patients on palliative care with regard to bowel function discomfort.”



 
  References Top

1.
Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009;155:11-7.  Back to cited text no. 1
    
2.
Sobczak M, Sałaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: Current concepts and future perspectives. J Gastroenterol 2014;49:24-45.  Back to cited text no. 2
    
3.
Nelson AD, Camilleri M. Opioid-induced constipation: Advances and clinical guidance. Ther Adv Chronic Dis 2016;7:121-34.  Back to cited text no. 3
    
4.
Vallerand AH. Opioid-induced Constipation. J Nurse Pract 13:170-174.e3. doi: 10.1016/j.nurpra.2016.11.006.  Back to cited text no. 4
    
5.
Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract 2014;2014:141737. doi:10.1155/2014/141737.  Back to cited text no. 5
    
6.
Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-8.  Back to cited text no. 6
    
7.
Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008;12:1040-6.  Back to cited text no. 7
    
8.
Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, et al. Gastrointestinal symptoms under opioid therapy: A prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009;13:737-43.  Back to cited text no. 8
    
9.
van Seventer R, Smit JM, Schipper RM, Wicks MA, Zuurmond WW. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin 2003;19:457-69.  Back to cited text no. 9
    
10.
Wong JO, Chiu GL, Tsao CJ, Chang CL. Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 1997;35:25-32.  Back to cited text no. 10
    
11.
Tassinari D, Sartori S, Tamburini E, Scarpi E, Tombesi P, Santelmo C, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: A meta-analysis of randomized clinical trials. J Palliat Care 2009;25:172-80.  Back to cited text no. 11
    
12.
Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: A meta-analysis and systematic review of the literature. J Palliat Med 2008;11:492-501.  Back to cited text no. 12
    
13.
Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R, et al. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588-93.  Back to cited text no. 13
    
14.
Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain 1996;64:527-34.  Back to cited text no. 14
    
15.
Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-fentanyl comparative trial group. J Pain Symptom Manage 1997;13:254-61.  Back to cited text no. 15
    
16.
Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine (Phila Pa 1976) 2005;30:2484-90.  Back to cited text no. 16
    
17.
Kanbayashi Y, Hosokawa T, Okamoto K, Fujimoto S, Konishi H, Otsuji E, et al. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain. Clin J Pain 2011;27:664-7.  Back to cited text no. 17
    
18.
Yang Q, Xie DR, Jiang ZM, Ma W, Zhang YD, Bi ZF, et al. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: A systematic review and meta-analysis. J Exp Clin Cancer Res 2010;29:67.  Back to cited text no. 18
    
19.
Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004;20:1419-28.  Back to cited text no. 19
    
20.
Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: Clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007;5:1126-39.  Back to cited text no. 20
    
21.
Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: Emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 2013;12:112-25.  Back to cited text no. 21
    
22.
Shah M, Huecker MR. Opioid Withdrawal. StatPearls Publishing; 2019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30252268. [Last accessed on 2019 Sep 18].  Back to cited text no. 22
    
23.
Frei A, Andersen S, Hole P, Jensen NH. A one year health economic model comparing transdermal fentanyl with sustained-release morphine in the treatment of chronic noncancer pain. J Pain Palliat Care Pharmacother 2003;17:5-26.  Back to cited text no. 23
    




 

Top
Print this article  Email this article
Online since 1st October '05
Published by Wolters Kluwer - Medknow